Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 1, 2026, 8:38 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 25 matching trials from the live ClinicalTrials.gov search.
Filters: Sponsor: Molecular NeuroImaging Clear all
Completed Early Phase 1 Interventional Accepts healthy volunteers

Phase 0 Evaluation of [18F]MNI-958 as a Potential PET Radioligand for Imaging Tau Protein in the Brain

NCT03058965
View directory record Official record
Conditions
Alzheimer Disease, Healthy Volunteers, Progressive Supranuclear Palsy
Interventions
[18F]MNI-958, [18F]Florbetapir, DaTscan
Drug
Lead sponsor
Molecular NeuroImaging
Other
Eligibility
50 Years to 90 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Mar 25, 2019 · Synced Oct 1, 2026, 8:38 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

Evaluation of [123I] MNI-308 and SPECT as a Marker of Beta-amyloid Protein Deposition in AD Subjects Compared to HC

NCT00544453
View directory record Official record
Conditions
Alzheimer Disease
Interventions
[123I] MNI-308
Drug
Lead sponsor
Molecular NeuroImaging
Other
Eligibility
50 Years and older
Enrollment
2 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Aug 21, 2009 · Synced Oct 1, 2026, 8:38 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Assessment of the Biodistribution and Safety of [18F]MNI-968 in Healthy Subjects

NCT03142724
View directory record Official record
Conditions
Healthy Volunteers
Interventions
[18F]MNI-968
Drug
Lead sponsor
Molecular NeuroImaging
Other
Eligibility
18 Years to 55 Years
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Mar 6, 2018 · Synced Oct 1, 2026, 8:38 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

Evaluation of [123I] MNI-330 and SPECT as a Marker of Beta-amyloid Protein Deposition

NCT00657813
View directory record Official record
Conditions
Alzheimer Disease
Interventions
MNI-330 as a brain SPECT tracer of Beta-Amyloid
Drug
Lead sponsor
Institute for Neurodegenerative Disorders
Other
Eligibility
50 Years and older
Enrollment
3 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Apr 3, 2019 · Synced Oct 1, 2026, 8:38 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Safety and Efficacy of Positron Emission Tomography (PET) Imaging With MNI-558

NCT01217021
View directory record Official record
Conditions
Alzheimer Disease
Interventions
[18F] MNI-558
Drug
Lead sponsor
Institute for Neurodegenerative Disorders
Other
Eligibility
55 Years and older
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jul 25, 2011 · Synced Oct 1, 2026, 8:38 AM EDT
Not listed Phase 2 Interventional Accepts healthy volunteers

A Study Evaluating Potential Screening Tools for Detecting Parkinson Disease

NCT00387075
View directory record Official record
Conditions
Parkinson Disease
Interventions
[123I]β-CIT and SPECT imaging, [123I]β-CIT
Procedure · Drug
Lead sponsor
Institute for Neurodegenerative Disorders
Other
Eligibility
50 Years and older
Enrollment
3,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2023
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Mar 29, 2022 · Synced Oct 1, 2026, 8:38 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

Assessment of the Biodistribution and Safety of 123-I MZINT in Healthy Subjects and Parkinson Disease Patients

NCT00427674
View directory record Official record
Conditions
Parkinson Disease
Interventions
[123I] mZINT injection and serial dynamic SPECT imaging
Drug
Lead sponsor
Institute for Neurodegenerative Disorders
Other
Eligibility
18 Years to 70 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2009
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Oct 6, 2010 · Synced Oct 1, 2026, 8:38 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Evaluation of [18F]MNI-815 as a Potential PET Radioligand for Imaging Tau Protein in the Brain of Patients With Tauopathies

NCT02531360
View directory record Official record
Conditions
Alzheimer's Disease (AD), Progressive Supranuclear Palsy (PSP), Cortical Basal Syndrome (CBS), Frontal Temporal Dementia (FTD)
Interventions
[18F]MNI-815 (MNI-815)
Drug
Lead sponsor
Molecular NeuroImaging
Other
Eligibility
50 Years to 90 Years
Enrollment
7 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Dec 16, 2016 · Synced Oct 1, 2026, 8:38 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Quantitative Evaluation of [18F]T807 as a Potential PET Radioligand for Imaging Tau in Patients With Alzheimer's Disease

NCT02370524
View directory record Official record
Conditions
Alzheimer's Disease (AD)
Interventions
[18F]T807
Drug
Lead sponsor
Molecular NeuroImaging
Other
Eligibility
20 Years to 90 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Mar 8, 2017 · Synced Oct 1, 2026, 8:38 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluation of Microglial Activation in ALS With [18F]PBR06 (Peripheral Benzodiazepine Receptor-06) PET

NCT03876002
View directory record Official record
Conditions
Healthy Volunteers, Amyotrophic Lateral Sclerosis
Interventions
[18F]PBR06
Drug
Lead sponsor
Molecular NeuroImaging
Other
Eligibility
18 Years to 80 Years
Enrollment
23 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Mar 26, 2019 · Synced Oct 1, 2026, 8:38 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluation of [18F]MNI-777 PET as a Marker of Tau Pathology in Subjects With Tauopathies Compared to Healthy Subjects

NCT02103894
View directory record Official record
Conditions
Alzheimer's Disease (AD), Parkinson's Disease (PD), Chronic Traumatic Encephalopathy (CTE), Progressive Supranuclear Palsy (PSP), Frontal Temporal Dementia (FTD), Pick's Disease, Tauopathies
Interventions
[18F]T807 ([18F]MNI-777)
Drug
Lead sponsor
Molecular NeuroImaging
Other
Eligibility
18 Years to 85 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Dec 16, 2016 · Synced Oct 1, 2026, 8:38 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

A Study of Neurophysiologic Changes in Individuals With Parkinson's Disease

NCT00117195
View directory record Official record
Conditions
Parkinson's Disease, Parkinsonian Syndrome
Interventions
Automated Neuropsychological Assessment Matrix
Device
Lead sponsor
Institute for Neurodegenerative Disorders
Other
Eligibility
22 Years and older
Enrollment
620 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2012
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Feb 9, 2012 · Synced Oct 1, 2026, 8:38 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluation of [123I] AV83 and SPECT in Patients With Alzheimer Disease in Comparison to Healthy Controls

NCT00448799
View directory record Official record
Conditions
Alzheimers Disease
Interventions
[123-I] AV-83 Injection and Imaging Procedures
Radiation
Lead sponsor
Molecular NeuroImaging
Other
Eligibility
50 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated May 13, 2008 · Synced Oct 1, 2026, 8:38 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Evaluation of [18F]MNI-952 as a Potential PET Radioligand for Imaging Tau Protein in the Brain

NCT03080051
View directory record Official record
Conditions
Progressive Supranuclear Palsy, Alzheimer Disease, Healthy Volunteers
Interventions
[18F]MNI-952, [18F]Florbetapir
Drug
Lead sponsor
Molecular NeuroImaging
Other
Eligibility
18 Years to 90 Years
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Oct 6, 2017 · Synced Oct 1, 2026, 8:38 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Biodistribution and Safety of a Radiopharmaceutical in Healthy Subjects

NCT00316797
View directory record Official record
Conditions
Neurodegenerative Diseases
Interventions
123-I INER
Drug
Lead sponsor
Institute for Neurodegenerative Disorders
Other
Eligibility
18 Years to 65 Years
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2014
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Apr 10, 2014 · Synced Oct 1, 2026, 8:38 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Efficacy and Safety of MNI-672 SPECT for Detection/Exclusion of Cerebral B-amyloid in AD Subjects Compared to HVs.

NCT01859767
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
[123I]MNI-672 SPECT
Drug
Lead sponsor
Molecular NeuroImaging
Other
Eligibility
20 Years and older
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Dec 16, 2016 · Synced Oct 1, 2026, 8:38 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

Assessment of the Effect of Sertaline on the Specific Binding of 123-I MZINT in Healthy Subjects

NCT00470925
View directory record Official record
Conditions
Depression
Interventions
123-I MZINT injection and SPECT imaging
Drug
Lead sponsor
Institute for Neurodegenerative Disorders
Other
Eligibility
18 Years to 70 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Apr 3, 2019 · Synced Oct 1, 2026, 8:38 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluation of [123I] MNI-187 and SPECT in Patients With Alzheimers Disease in Comparison to Healthy Subjects

NCT00456417
View directory record Official record
Conditions
Alzheimers Disease
Interventions
123-I MNI-187 Injection and Imaging Procedures
Drug
Lead sponsor
Institute for Neurodegenerative Disorders
Other
Eligibility
50 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Mar 14, 2019 · Synced Oct 1, 2026, 8:38 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Assess 123-I IMPY and SPECT Imaging as a Tool to Detect β-Amyloid in the Brain

NCT00287248
View directory record Official record
Conditions
Alzheimer Disease
Interventions
[123I] IMPY & SPECT Imaging
Drug
Lead sponsor
Institute for Neurodegenerative Disorders
Other
Eligibility
50 Years and older
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2008
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Mar 7, 2014 · Synced Oct 1, 2026, 8:38 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Phase 0 Study of [18F]MNI-968 as a Marker for D1 Receptor in Healthy Subjects

NCT03082768
View directory record Official record
Conditions
Healthy Volunteers
Interventions
[18F]MNI-968
Drug
Lead sponsor
Molecular NeuroImaging
Other
Eligibility
18 Years to 50 Years
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Mar 6, 2018 · Synced Oct 1, 2026, 8:38 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Use of [123I] AV39 and SPECT Imaging as a Marker of Protein Disposition in Subjects With Alzheimer Disease Compared to Healthy Subjects

NCT00439010
View directory record Official record
Conditions
Alzheimers Disease
Interventions
[123I] AV 39
Drug
Lead sponsor
Molecular NeuroImaging
Other
Eligibility
50 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Apr 24, 2008 · Synced Oct 1, 2026, 8:38 AM EDT
Completed Phase 2 Interventional

Study of Individuals With Parkinson's Symptoms But in Whom There is Diagnostic Uncertainty

NCT00129675
View directory record Official record
Conditions
Parkinsonian Syndrome
Interventions
[123I]ß CIT
Drug
Lead sponsor
Institute for Neurodegenerative Disorders
Other
Eligibility
21 Years and older
Enrollment
169 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2009
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jul 16, 2014 · Synced Oct 1, 2026, 8:38 AM EDT
Completed Phase 2 Interventional

Imaging and Genetic Biomarkers of Parkinson Disease (PD) Onset and Progression in High-risk Families

NCT00273351
View directory record Official record
Conditions
Parkinson Disease, Parkinsonian Syndrome
Interventions
[123I]B-CIT
Drug
Lead sponsor
Institute for Neurodegenerative Disorders
Other
Eligibility
21 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated May 9, 2014 · Synced Oct 1, 2026, 8:38 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

ALTROPANE® SPECT Imaging in Patients With Parkinson Disease

NCT00397228
View directory record Official record
Conditions
Parkinson Disease
Interventions
ALTROPANE®
Drug
Lead sponsor
Molecular NeuroImaging
Other
Eligibility
30 Years and older
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2011
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Dec 16, 2016 · Synced Oct 1, 2026, 8:38 AM EDT